SRC

Stallion Uranium Drilling Intersects Anomalous Radioactivity

Retrieved on: 
Tuesday, April 2, 2024
SRC, La Loche, QA/QC, CPS, TDEM, National Instrument 43-101, Coffer, Blue square, Uranium, Boron, Appaloosa, ICP-OES, Radioactive decay, HF, ICP-MS, HNO3, National instrument, Standards Council of Canada, Fracture, Green Square, BGO, Clay, Athabasca Basin

The survey data when compiled and modeled with all available historical data showed the key characteristics for potential uranium mineralization.

Key Points: 
  • The survey data when compiled and modeled with all available historical data showed the key characteristics for potential uranium mineralization.
  • To best refine drill targets Stallion utilized the latest technology to complete an advanced ground TDEM survey over the target area.
  • Stallion Uranium requests multi-element analysis by ICP-MS and ICP-OES using total (HF:NHO3:HClO4) and partial digestion (HNO3:HCl), boron by fusion.
  • The foregoing scientific and technical disclosures for Stallion Uranium have been reviewed by Darren Slugoski, P.Geo., VP Exploration, a registered member of the Professional Engineers and Geoscientists of Saskatchewan.

Leviton Expands Smart Sensor Line with Smart Ceiling Mount Room Controllers and Sensors

Retrieved on: 
Tuesday, April 9, 2024
Sequence, SRC, Dimmer, Leviton, Part, Smart, 90.1 FM, ASHRAE, IECC, Smart sensor, CMS, Sensor

MELVILLE, N.Y., April 9, 2024 /PRNewswire/ -- Leviton today announced the expansion of the Smart Sensor line with Smart Ceiling Mount Room Controllers (SRC) and Smart Ceiling Mount Sensors (CMS). The line simplifies advanced lighting controls by integrating several control strategies into a self-contained, cost-effective, and easy-to-install device. By requiring just two devices instead of the industry's standard four for code compliance requirements, the solutions streamline installation.

Key Points: 
  • MELVILLE, N.Y., April 9, 2024 /PRNewswire/ -- Leviton today announced the expansion of the Smart Sensor line with Smart Ceiling Mount Room Controllers (SRC) and Smart Ceiling Mount Sensors (CMS).
  • "Our Smart Ceiling Mount Room Controllers and Sensors provide an industry-exclusive powerhouse solution, requiring just two devices to install for a complete lighting control system, rather than the industry's typical four.
  • Smart Ceiling Mount Room Controllers and Smart Ceiling Mount Sensors can be used to comply with IECC, ASHRAE 90.1, and 2022 Title 24, Part 6 occupancy/vacancy sensing, dimming, partial-ON, partial-OFF, daylight harvesting, plug load control, and demand response requirements.
  • For more information on the Smart Ceiling Mount Room Controllers and Smart Ceiling Mount Sensors, visit www.leviton.com/smartsensors .

OpenStamp Hits $50 Million Valuation in Seed Round Led by Animoca Ventures and KuCoin Ventures

Retrieved on: 
Friday, March 22, 2024
SRC, Launch pad, Growth, Ecosystem

As a pioneer leader for the SRC ecosystem, their products include Mint/Deploy service, SRC-20/SRC-721 Marketplace, Indexer, Explorer, and their Launchpad.

Key Points: 
  • As a pioneer leader for the SRC ecosystem, their products include Mint/Deploy service, SRC-20/SRC-721 Marketplace, Indexer, Explorer, and their Launchpad.
  • With great excitement, the completion of their seed round is announced, crossing a valuation of $50 million.
  • This milestone was made possible through the leadership of Animoca Ventures and KuCoin Ventures.
  • As OpenStamp continues to expand and refine its platform, it eagerly anticipates the opportunity to serve its users and contribute to the growth of the SRC ecosystem.

Pan American Energy Collaborates With The Saskatchewan Research Council For Preliminary Metallurgical Testing To Produce Petalite Concentrates

Retrieved on: 
Monday, March 18, 2024
Lithium, Saskatchewan Research Council, SRC, Technical report, Associate, Big Mack, News, HLS, Glass, Phase 1

In 1999, the former operator of Big Mack removed a representative 5000 tonne bulk sample from the Big Mack Pegmatite exposure.

Key Points: 
  • In 1999, the former operator of Big Mack removed a representative 5000 tonne bulk sample from the Big Mack Pegmatite exposure.
  • This sample was processed by International Metallurgical and Environmental Inc. to create petalite concentrate.
  • The petalite concentrate was then sent to Corning Laboratory Services of Corning, New York for petalite analysis and trial glass metals, where three glass melts were made using the supplied petalite.
  • The petalite yielded glass of acceptable visual quality, validating the opportunity for commercial offtake partners of the petalite concentrate material.

SRC Digital Insurance Services Spearheads Crowdfunding Campaign to Digitally Connect Renewable Energy Stakeholders with Capital and Financial Markets

Retrieved on: 
Wednesday, April 3, 2024
Metaverse, Banking, Professional Services, Utilities, Fintech, Sustainability, Alternative Energy, Energy, Technology, Environment, Insurance, Finance, SRC, Partnership, Financial management, Cryptocurrency

SRC Digital Insurance Services has kicked off the crowdfunding campaign for Blu Opportunity with K. Dixon Wright as its lead investor.

Key Points: 
  • SRC Digital Insurance Services has kicked off the crowdfunding campaign for Blu Opportunity with K. Dixon Wright as its lead investor.
  • Crowdfunding is transforming the renewable energy sector as entrepreneurs can now access startup capital to create next generation products and services that operate in digital ecosystems, the Metaverse.
  • "With the urgent need to connect renewable energy initiatives with the capital and financial markets more efficiently, our partnerships are more than strategic collaborations; they are a leap towards redefining the financial landscape of the renewable energy sector," said K. Dixon Wright, President of SRC Digital Insurance Services.
  • "By joining forces with SRC Digital Insurance Services we are setting the stage for a future where digital solutions pave the way for significant advancements in renewable energy financing."

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Retrieved on: 
Friday, March 29, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Lung cancer, EGFR, SRC, NSCLC, Patient, Breakthrough therapy, Trial of the century, DLT, Clinical trial, PACC, HKEX, FDA, SHP2, Food, Pharmaceutical industry

In July 2023, InnoCare and ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced a clinical development collaboration, accelerating the clinical trial of ICP-189 in combination with furmonertinib in patients with advanced or metastatic NSCLC in China.

Key Points: 
  • In July 2023, InnoCare and ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced a clinical development collaboration, accelerating the clinical trial of ICP-189 in combination with furmonertinib in patients with advanced or metastatic NSCLC in China.
  • Furmonertinib is being advanced by ArriVent in global studies in patients with advanced or metastatic NSCLC with EGFR mutations, including exon 20 insertion mutations.
  • Furmonertinib is also being evaluated for the treatment of NSCLC patients with EGFR P-loop alpha-c helix compressing (PACC) mutations.
  • We will accelerate the clinical study and expect this innovative therapy to benefit more NSCLC patients early.”

WiSA Technologies Adds Additional Functionality to its Powerful WiSA E Immersive Audio Software

Retrieved on: 
Monday, March 25, 2024
Software, Mobile, Wireless, Entertainment, Hardware, Consumer Electronics, Technology, Other Manufacturing, Other Entertainment, TV and Radio, Audio, Video, Electronic Games, Manufacturing, Platin, Bang & Olufsen, SRC, DTS, ATMOS, Sport, CE, Name, WiSA, Electronics, TCL, Wireless speaker, Ecosystem, Music, Harman International, PTV, Video game

WiSA Technologies, Inc. (NASDAQ: WISA), a leading innovator in wireless audio technology for intelligent devices and next-generation home entertainment systems, announces the addition of two features to its WiSA E wireless immersive audio software stack.

Key Points: 
  • WiSA Technologies, Inc. (NASDAQ: WISA), a leading innovator in wireless audio technology for intelligent devices and next-generation home entertainment systems, announces the addition of two features to its WiSA E wireless immersive audio software stack.
  • WiSA Technologies, Inc. (NASDAQ: WISA) is a leading provider of immersive, wireless sound technology for intelligent devices and next-generation home entertainment systems.
  • WiSA Technologies, Inc. and the WiSA Technologies, Inc. logo are trademarks of WiSA Technologies, Inc.
  • The WiSA logo, WiSA®, WiSA Ready™, and WiSA Certified™ are trademarks and certification marks of WiSA, LLC.

Clarkson University Announces New Cybersecurity Masters Program

Retrieved on: 
Monday, March 25, 2024
SRC, Risk management, Computer science, AIS, Education, OSS, Internet, Research, Artificial intelligence, Clarkson University, University, AI, Postgraduate education, Computer engineering, Electricity, Unisys, IBM, VMware, Student, NIST, Master, Lockheed Martin, Machine learning, Multimedia, COSI, Government

Clarkson University is rising to meet this challenge by offering a new Masters degree in Cybersecurity.

Key Points: 
  • Clarkson University is rising to meet this challenge by offering a new Masters degree in Cybersecurity.
  • The depth and range of research in the field of Cybersecurity already being conducted by Clarkson University faculty serves to bolster the education of students entering the program.
  • Students in Clarkson's Cybersecurity program will have access to a variety of resources, including the Clarkson Open Source Institute (COSI) .
  • For more information about the Cybersecurity degree program at Clarkson University, visit clarkson .edu/cybersecurity .

TECNO's Security Response Center Authorized by the CVE Program

Retrieved on: 
Tuesday, March 19, 2024
SRC, Organization, Communication, Intelligence, Software, Catalog, CNA, CVE, Medical device

HONG KONG, March 19, 2024 /PRNewswire/ -- Innovative technology brand TECNO is pleased to announce that it has been authorized by the Common Vulnerabilities and Exposures (CVE®) Program as a CVE Numbering Authority (CNA).

Key Points: 
  • HONG KONG, March 19, 2024 /PRNewswire/ -- Innovative technology brand TECNO is pleased to announce that it has been authorized by the Common Vulnerabilities and Exposures (CVE®) Program as a CVE Numbering Authority (CNA).
  • As a partner of the program, or "CNA", TECNO is authorized to publish vulnerabilities it discovers to the CVE List – the catalog of all published CVE records – within its specified scope.
  • TECNO first established its official Security Response Center (SRC) in September 2021.
  • The SRC is a platform that allows the brand to collect and investigate security vulnerabilities and intelligence reports, while also facilitating communications with security professionals and organizations.

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Retrieved on: 
Wednesday, March 13, 2024
SRC, Week, Cirrhosis, ALT, Disease, Safety, Part, Patient, GPR119, Aes, Șaeș, Alanine transaminase, MASH, Clinical trial, Type, Liver disease, T2DM, Triglyceride, Pharmaceutical industry

CAMBRIDGE, Mass., March 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced receipt of Safety Review Committee (SRC) approval, recommending that the two-part Phase 2a trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), continue without modification following a blinded safety review of the first six months of study conduct. The Phase 2a clinical trial is designed to evaluate the efficacy and safety of DA-1241, for the treatment of MASH. The company anticipates a full data readout from the trial in the second half of 2024.

Key Points: 
  • The Phase 2a clinical trial is designed to evaluate the efficacy and safety of DA-1241, for the treatment of MASH.
  • The company anticipates a full data readout from the trial in the second half of 2024.
  • Each of the two-parts of the Phase 2a trial of DA-1241 are designed to be 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel clinical studies to evaluate the efficacy and safety of DA-1241 in subjects with presumed MASH.
  • Subjects will be randomized in a 1:2:1 ratio into 3 treatment groups: DA-1241 50 mg, DA-1241 100 mg, or placebo.